Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.37 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329918 | 0.83 | SLC7A5 (0.41) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL515168 | 0.82 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL359673 | 0.82 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL8368782 | 0.82 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL8182501 | 0.79 | CACNA2D1 (0.57) | SLC7A5CACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL17298648 | 0.79 | CACNA2D1 (0.57) | SLC7A5CACNA2D1CACNB3CACNA1CPGR | |
| Aspartic Acid SCHEMBL26964971 | 0.73 | GRIK1 (0.54) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL20898108 | 0.73 | GRIK1 (0.54) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL26612391 | 0.73 | GRIK1 (0.54) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL28258139 | 0.73 | GRIK1 (0.54) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023245169-A1 | ANTIMICROBIAL PEPTIDE COMBINATIONS | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | claimed |
| CN-102256610-A | Probiotic formulations | BRACCO IMAGING SPA | 2011-11-23 | — | — | CN | claimed |
| EP-4727957-A2 | PVD1 VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024259306-A2 | PVD1 VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2024-12-19 | — | — | WO | disclosed |
| US-11905323-B2 | Recombinant chimeric protein for selectins targeting | Bracco Suisse (CH) | 2024-02-20 | — | — | US | disclosed |
| WO-2023245100-A1 | ANTIMICROBIAL NCR13 VARIANT PEPTIDES | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023245169-A1 | ANTIMICROBIAL PEPTIDE COMBINATIONS | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20220389080-A1 | RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING | BRACCO SUISSE SA (CH) | 2022-12-08 | — | — | US | disclosed |
| US-11370826-B2 | Recombinant chimeric protein for selectins targeting | BRACCO SUISSE SA (CH) | 2022-06-28 | — | — | US | disclosed |
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | BRACCO IMAGING S.P.A. (IT) | 2012-06-28 | — | — | US | disclosed |
| CN-102256610-A | Probiotic formulations | BRACCO IMAGING SPA | 2011-11-23 | — | — | CN | disclosed |
| CN-102105174-A | Diagnostic agents selective for metalloproteases | BRACCO IMAGING SPA | 2011-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905323-B2 | Recombinant chimeric protein for selectins targeting | SELPLG, SELL, SELE | SLC7A5 1299/4885SLC1A3 1982/4885SLC1A2 1966/4885 |
| US-20220389080-A1 | RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING | SELPLG, SELL, SELE | SLC7A5 1299/4885SLC1A3 1982/4885SLC1A2 1966/4885 |
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | TAGLN2, TTN, TXLNA | SLC7A5 3938/4885SLC1A3 4376/4885SLC1A2 4824/4885 |
| US-11370826-B2 | Recombinant chimeric protein for selectins targeting | SELPLG, SELL, SELE | SLC7A5 1299/4885SLC1A3 1982/4885SLC1A2 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.